Navigation Links
Senesco and Harris Moran Mutually Agree to Terminate Development and License Agreement Due to Restructuring
Date:12/5/2008

NEW BRUNSWICK, N.J., Dec. 5 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Alternext US: SNT) announced today that its Development and License Agreement with the http://www.senesco.com ("Harris Moran") has been terminated by mutual agreement because of Harris Moran's recently announced corporate restructuring.

Harris Moran has reported that its parent company, Limagrain, restructured its vegetable seed operations and that Harris Moran will now be part of a new Business Unit with Clause (France) and Marco Polo (Thailand). This restructuring has resulted in a consolidation of R&D efforts amongst Harris Moran and its sister companies that will not encompass Senesco's technology. Harris Moran made Senesco aware of this shift in R&D focus and presented the Company with a letter on December 1, 2008 formally ending the relationship through the mutual agreement of the parties.

Pursuant to the terms of the Development and License Agreement all rights to use Senesco's technology in lettuce and melon revert to Senesco.

About Senesco Technologies, Inc.

Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain diseases inflammatory and ischemic diseases. Senesco takes its name from the scientific term for the aging of plant cells: senescence. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products.

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, our ability to maintain our continued listing standards for the next 12 months, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

    Company Contact:
    Senesco Technologies, Inc.
    Bruce Galton
    Chief Executive Officer
    (bgalton@senesco.com)
    (732) 296-8400

    Investor Relations Contact:
    FD
    Brian Ritchie
    (brian.ritchie@fd.com)
    (212) 850-5600


'/>"/>
SOURCE Senesco Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Senesco Appoints Harlan W. Waksal, M.D., to Board of Directors
2. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
3. Senesco Technologies Announces Successful Completion of First Milestone Related to Agreement with Bayer CropScience
4. Senesco Technologies Closes Remaining $3.0 Million of Previously Announced Financing
5. Senesco Signs a Supply Agreement for Polyplus-transfections Delivery System
6. Senesco Technologies to Present at BIO 2008 Business Forum
7. Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results
8. Senesco Technologies Regains Compliance With Amexs Continued Listing Requirements
9. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
10. Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies
11. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... 2017   Valentin A. Pavlov, PhD , associate ... and CEO of The Feinstein Institute for Medical ... how the nervous system regulates the immune system, which ... medicine devices to treat disease and injury. The ... The paper examines various studies which further ...
(Date:1/13/2017)... 2017 Research and Markets has announced the ... Global Forecast to 2021" report to their offering. ... The biosimilars market is ... Billion in 2016, at a CAGR of 26.3%. ... manufacturing type, and application. Factors such as rising incidence of various ...
(Date:1/12/2017)... ... January 12, 2017 , ... MEXICO’S FIRST ... Inc., announces the successful outcome of the first lumbar fusion procedure in ... Technologies, Inc.) has partnered with Mexico-based medical product company BioMedical Technologies to ...
(Date:1/12/2017)... , January 12, 2017 The ... world,s biggest facility for producing mycorrhizae. The Centre for ... tapping potential of mycorrhizae and developed a technology that ... ... The TERI facility has a ...
Breaking Biology Technology:
(Date:12/15/2016)... FREMONT, Calif. , Dec. 15, 2016   ... a publicly held genomics technology company, announced today that ... the Listing Qualifications Department of The Nasdaq Stock Market ... the closing bid price of WaferGen,s common stock had ... days.  Accordingly, WaferGen has regained compliance with Listing Rule ...
(Date:12/15/2016)... LONDON , Dec. 15, 2016 /PRNewswire/ ... the driving experience, health wellness and wellbeing ... As one in three new passenger vehicles ... voice recognition, gesture recognition, heart beat monitoring, ... eyelid monitoring, facial monitoring, and pulse detection. ...
(Date:12/15/2016)... "Increase in mobile transactions is driving the growth of ... expected to grow from USD 4.03 billion in 2015 ... of 29.3% between 2016 and 2022. The market is ... smart devices, government initiatives, and increasing penetration of e-commerce ... to grow at a high rate during the forecast ...
Breaking Biology News(10 mins):